Biotech / Medical
Regeneron Pharmaceuticals
An SI Board Since May 1996
Posts SubjectMarks Bans Symbol
2251 95 0 REGN
Emcee:  Patrick Slevin Type:  Unmoderated
Regeneron (REGN) is a biotech working in recombinant DNA technology. Until '94 it generally traded between 10 and 20 dollars until the FDA beat it up on it's treatment for Lou Gehrig's Disease. While it was trading at the $4 level at the end of '94, the former chairman of Merck(I believe) took the helm and the stock climbed back to about 11, then traded between 11 and 14. In late May, Option volume increased, news about a discovery concerning muscles was announced, and the stock has risen sharply to Friday, May 24 '96 close of 18.875.

Historically, the stock has failed around 22. Yet AMGEN has more than a 17.7% stake with warrants to increase it's stake to 20%, at 16$ per share. Could this be the time it breaks out?
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
2251To make it clear, in trial: They already have triple combinMiljenko Zuanic-Tuesday
2250Will see how long it will take them to emend protocol? REGN is in control of theMiljenko Zuanic-Tuesday
2249Yes, they should be testing chemo ± REGN 2810 (not head-to-head).DewDiligence_on_SI-Tuesday
2248In light of the latest Keytruda/chemo results for any PDL1 level in 1L NSCLC, REMiljenko Zuanic-Tuesday
2247Last time BI Ridgefield facility were inspected by FDA was 2-2017, no 483 letterMiljenko Zuanic-January 11
2246I know their Ridgefield site was going through a lot of turnover and struggles tFelix B-January 10
2245BI is serious player in antibody manufacturing business, regardless where are maMiljenko Zuanic1January 10
2244"Boehringer Ingelheim’s world-class biopharmaceutical manufacturing facilitFelix B-January 10
2243BGNE PD-1 candidate, BGBA317, is closing in: Miljenko Zuanic-January 10
2242Musings on MYL/MNTA's decision to pursue an Eylea FoB: siliconinvestor.comDewDiligence_on_SI-January 8
2241CHRS is another company developing an Eylea biosimilar, although its program is DewDiligence_on_SI-January 8
2240I intend to keep most of my REGN shares as well. It's been a long ride fromBiotech Jim-January 8
2239<Today investors vote: NO! Clearly!> And as regular contrarian, my vote iMiljenko Zuanic1January 8
2238Would investment in "spending" ever pay off at REGN??? files.shareholdMiljenko Zuanic-January 8
2237Go BCRX, go: Zuanic-January 5
2236RSI and Stochastic oscillator are triggering buying signal. [graphic]Alejandroo Green-January 4
2235There is no sustained release formulation. 6-8w (up to 12w in some cases) is finMiljenko Zuanic-January 4
2234I agree I thought a biosimilar trap would be difficult to produce but I am no exFelix B-January 3
2233<I checked REGN balance shits, and am happy that they improve it. Hope, it maMiljenko Zuanic-January 3
2232Marry Christmas to ALL!Miljenko Zuanic-12/24/2017
2231Seams like tax obligation sale. He has "plenty", so I do not fill sorrMiljenko Zuanic112/21/2017
2230GY, Rule 10b5-1(c) filing! investor.regeneron.comBiotech Jim-12/20/2017
2229It is difficult to value targets, but at least they are doing something (in acceMiljenko Zuanic-12/14/2017
2228Thoughts on these targets? How is competitive landscape out there?Felix B-12/14/2017
2227In addition to anti-LAG3, they also have anti-GITR Abs in development: appft.uspMiljenko Zuanic-12/14/2017
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
Copyright © 1995-2018 Knight Sac Media. All rights reserved.Stock quotes are delayed at least 15 minutes - See Terms of Use.